Sep 2026· International Journal of Molecular Sciences· Vol 27, pp. 8045· 0 citations· 58 references
Medicine
TL;DR
It is demonstrated that increasing deoxyribonucleoside triphosphate (dNTP) levels impairs HR-mediated double-strand break repair, rendering GBM cells sensitive to IR and Temozolomide and uncovering a promising vulnerability that could be exploited to overcome resistance to DNA-damaging treatments in GBM and beyond.
Abstract
Glioblastoma (GBM) standard of care includes surgical resection followed by ionizing radiation (IR) and Temozolomide, which induce DNA double-strand breaks. Homologous recombination (HR), a critical DNA double-strand break repair pathway, is augmented in GBM, contributing to resistance and poor patient outcomes. Here, we demonstrate that increasing deoxyribonucleoside triphosphate (dNTP) levels impairs HR-mediated double-strand break repair, rendering GBM cells sensitive to IR and Temozolomide. Interestingly, combining an elevated dNTP pool level with IR and/or Temozolomide promotes the recruitment of DNA polymerase-α/primase, which is typically involved in Okazaki fragment synthesis during DNA replication, to the DNA double-strand break site, thereby interfering with DNA end resection. Specifically, higher dNTP pool levels disrupted the recruitment of HR-associated proteins such as RPA70 and RAD51, an effect reversed by Aphidicolin, a DNA polymerase-α/primase inhibitor. Impaired HR delayed IR- and/or Temozolomide-induced DNA double-strand break repair, leading to growth arrest and apoptosis. Furthermore, higher dNTP pool levels led to downregulation of DNA replication and HR-associated genes, while upregulating several pro-apoptotic genes. Increased sensitivity to IR and Temozolomide was also observed in engineered IR-resistant GBM cell lines and in naturally recurrent patient-derived GBM cells that emerge post-therapy. These findings emphasize how dNTP pool levels regulate HR and uncover a promising vulnerability that could be exploited to overcome resistance to DNA-damaging treatments in GBM and beyond.
Poly(ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality to treat BRCA1/2-mutated ovarian cancer, yet clinical responses are often incomplete and resistance frequently emerges. PARPi exert cytotoxic effects by inhibiting single-strand break repair and trapping PARP on DNA, which impedes replication fo...
Na Li, Kousalya Lavudi, Qian-Yun Ge et al.· Cancer Research· 0 citations
ABSTRACT While cytotoxic chemotherapy remains the backbone of systemic treatments for triple‐negative breast cancer (TNBC), patients frequently develop resistance and recurrence, leading to poor clinical outcomes. However, molecular mechanisms underlying chemotherapy resistance are enigmatic. In this study, a pivotal e...
R. Kumari, Jia Fang· Advancement of science· 0 citations
Cisplatin resistance in hepatoblastoma (HB) is a major therapeutic barrier. Emerging evidence suggests that cancer cells can activate DNA double-strand break repair pathways to evade chemotherapy-induced apoptosis and sustain stemness; however, the mechanisms underlying cisplatin resistance in HB remain poorly understo...
Ze-Yu Yan, Qian Wang, Jing Li et al.· Pharmacological Research· 0 citations
Homologous recombination (HR) is a high-fidelity DNA repair pathway responsible for the resolution of double-strand breaks, with the RAD51 recombinase playing a pivotal role through the formation of nucleoprotein filaments on single-stranded DNA. Overexpression of RAD51 is frequently observed in cancer cells, where it...
Lucie Fonteneau, H. Benhelli-Mokrani, Céline Robiou Du Pont et al.· Biochemical Pharmacology· 0 citations
Extrachromosomal DNA (ecDNA) comprises megabase-sized circular DNA elements that frequently carry oncogene amplifications, driving aggressive tumour phenotypes, therapeutic resistance and poor clinical outcomes across many cancers1, 2, 3–4. Although ecDNA is thought to arise from canonical double-strand break repair, t...
David Billing, Monica Selvaraj, M. E. Kelley et al.· Nature· 1 citation
G17, a small molecule that selectively inhibits monopolar spindle 1 (Mps1), the central kinase controlling SAC signaling, is developed and provided pharmacological evidence that disrupting SAC signaling can expose a DNA repair vulnerability in glioblastoma.
Gaurav Rai, S. Kirubakaran· Journal of Biological Chemis...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.